EndoGastric Solutions
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $5.0m | Series A | |
| N/A | $12.0m | Series B | |
| N/A | $32.0m | Series C | |
$30.0m | Series D | ||
| N/A | $7.5m | Late VC | |
| N/A | $9.5m | Late VC | |
| N/A | $30.0m | Series F | |
| N/A | $21.5m | Series E | |
| N/A | $2.1m | Late VC | |
| N/A | $13.0m | Late VC | |
| N/A | $10.0m | Debt | |
$30.0m | Series G | ||
| N/A | $10.0m | Late VC | |
$50.0m | Late VC | ||
$30.5m | Late VC | ||
$15.0m | SERIES I | ||
| N/A | $27.0m | Late VC | |
* | N/A | $18.0m Valuation: $135m | Late VC |
| Total Funding | €312m | ||
Related Content
Recent News about EndoGastric Solutions
EditEndoGastric Solutions is a pioneering company in the medical field, focusing on the endoluminal treatment of digestive diseases, particularly Gastroesophageal Reflux Disease (GERD). The company operates in the healthcare market, providing advanced medical procedures and devices to physicians and healthcare providers. Their core product, the Transoral Incisionless Fundoplication (TIF) procedure, offers a minimally invasive solution for GERD sufferers, aiming to improve patient outcomes and quality of life. EndoGastric Solutions generates revenue through the sale of their proprietary medical devices, training programs for physicians, and ongoing support services. The company serves a wide range of clients, including hospitals, clinics, and individual healthcare practitioners. By leveraging innovative technology and clinical research, EndoGastric Solutions positions itself as a leader in its niche market.
Keywords: GERD, TIF procedure, endoluminal treatment, digestive diseases, minimally invasive, medical devices, healthcare providers, patient outcomes, clinical research, physician training.